ARMP
Armata Pharmaceuticals Inc
3.70$
+3.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3,073.8% | -2,059.2% | -4,072.7% | -7,993.0% | – | -50,264.5% | -2,219.9% | -526.9% | -589.7% | -1,047.1% | -725.8% | -525.3% | |
| 38.6% | 69.5% | 141.9% | 325.2% | – | 4,358.1% | 135.4% | 26.1% | 16.2% | 21.5% | 25.6% | 31.2% | |
| 473.3% | 101.7% | 767.3% | 608.7% | – | 13,777.4% | 422.2% | 64.4% | 56.4% | 20.7% | 55.9% | 53.2% | |
| – | – | – | 254.8% | – | 15,274.2% | 446.1% | 76.3% | 70.8% | – | – | – | |
| -135.9% | -33.3% | 257.7% | -397.4% | – | -7,061.3% | -106.2% | -72.0% | 8.0% | -213.0% | -40.6% | -28.8% | |
| 293.9% | 44.2% | 107.3% | 50.4% | – | 422.6% | 100.1% | 29.1% | 40.1% | 179.8% | 36.3% | 11.1% | |
| -293.9% | -44.2% | -107.3% | -50.4% | – | 9,280.6% | -100.1% | -29.1% | -40.1% | -179.6% | -36.3% | -11.1% | |
| – | – | 30.8% | 0.0% | – | – | – | – | – | – | – | – | |
| – | 2,690.5% | -66.5% | 8,248.7% | – | 32,177.4% | 2,802.1% | 602.0% | 808.2% | -0.9% | – | – | |
| – | – | – | 623.5% | – | 2,312.9% | 87.1% | 0.0% | -9.1% | 1,192.9% | 674.3% | 509.8% | |
| – | 2,690.5% | 2,772.7% | 7,540.0% | – | 28,951.6% | 2,820.2% | 570.4% | 799.1% | 1,192.1% | 675.6% | 522.3% | |
| -3,367.7% | 587.2% | -1,407.3% | -503.5% | – | -12,032.3% | 500.1% | 14.3% | 82.9% | -34.6% | -86.4% | -14.1% | |
| -3,367.7% | -2,103.4% | -4,180.0% | -8,043.5% | – | -50,687.1% | -2,320.0% | -556.1% | -629.8% | -1,226.9% | -762.1% | -536.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.